

ABRAPLATA RESOURCE CORP.
(formerly Angel Bioventures Inc.)

Consolidated Financial Statements
December 31, 2017
(expressed in Canadian dollars)



Crowe MacKay LLP
Member Crowe Horwath International
1100 - 1177 West Hastings Street
Vancouver, BC V6E 4T5
+1.604.687.4511 Tel
+1.604.687.5805 Fax
+1.800.351.0426 Toll Free
www.crowemackay.ca

Independent Auditor's Report

To the Shareholders of AbraPlata Resource Corp.

We have audited the accompanying consolidated financial statements of AbraPlata Resource Corp. and its subsidiaries, which comprise the consolidated statements of financial position as at December 31, 2017 and September 30, 2016, and the consolidated statements of operations and comprehensive (income) loss, changes in equity, and cash flows for the periods then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of AbraPlata Resource Corp. and its subsidiaries as at December 31, 2017 and September 30, 2016 and its financial performance and its cash flows for the periods then ended in accordance with International Financial Reporting Standards.

Emphasis of matter

Without modifying our opinion, we draw attention to Note 1 to the consolidated financial statements which describes the material uncertainty that may cast significant doubt about the ability of AbraPlata Resource Corp. to continue as a going concern.

"Crowe MacKay LLP"

**Chartered Professional Accountants
Vancouver, British Columbia
April 30, 2018**

ABRAPLATA RESOURCE CORP.
(formerly Angel Bioventures Inc)
Consolidated Statements of Financial Position
(Expressed in Canadian dollars)

	As at	
	December 31, 2017	September 30, 2016
ASSETS		
Current assets		
Cash	\$ 22,223	\$ 295,594
Receivable	69,082	7,636
Prepaid	17,796	-
	109,101	303,230
Non-current assets		
Mineral interests (note 7)	4,857,051	39,352
TOTAL ASSETS	\$ 4,966,152	\$ 342,582
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities (note 10)	\$ 1,264,839	\$ 170,901
SHAREHOLDERS' EQUITY		
Share capital (note 9)	18,105,909	8,192,023
Reserves	1,377,442	-
Accumulated other comprehensive loss	(763,588)	(735,073)
Accumulated deficit	(15,018,450)	(7,285,269)
TOTAL SHAREHOLDERS' EQUITY	3,701,313	171,681
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 4,966,152	\$ 342,582

Nature of operations and continuance of business (Note 1)
Commitments (Notes 7, 12)
Events after the reporting date (Notes 7, 9, 14)

Approved on behalf of the Board of Directors on April 30, 2018:

Dave Doherty
Director

Hernan Zaballa
Director

The accompanying notes are an integral part of these consolidated financial statements.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc)

Consolidated Statements of Operations and Comprehensive (Income) Loss

(Expressed in Canadian dollars)

	Fifteen months ended December 31, 2017	Twelve months ended September 30, 2016
ADMINISTRATIVE EXPENSES		
Accounting and audit	\$ 84,029	\$ -
Consulting fees (note 10)	124,671	272,389
Directors' fees (note 10)	514,462	81,676
Impairment of mineral interests (note 7)	27,378	-
Insurance	39,352	-
Interest	302,684	-
Investor relations	368,762	58,834
Legal	194,843	-
Office and administration (note 10)	287,402	5,427
Rent	68,628	-
Salary and benefits	51,324	-
Share-based payments (notes 9 and 10)	875,340	-
Transfer agent and filing fees	41,849	16,000
Travel	69,062	-
	<hr/> 3,049,786	<hr/> 434,326
EVALUATION AND EXPLORATION EXPENSES (note 8)	2,392,861	252,199
OTHER (INCOME) EXPENSES		
Debt forgiveness	-	(2,965,694)
Listing transaction expense (note 5)	2,268,688	-
Foreign exchange	21,846	(17,119)
	<hr/> 2,290,534	<hr/> (2,982,813)
NET (INCOME) LOSS FOR THE PERIOD	7,733,181	(2,296,288)
OTHER COMPREHENSIVE (INCOME) LOSS		
Unrealized (gain) loss on translation to reporting currency	28,515	(90,346)
COMPREHENSIVE (INCOME) LOSS	<hr/> \$ 7,761,696	<hr/> \$ (2,386,634)
LOSS (EARNINGS) PER SHARE basic and diluted	<hr/> \$ 0.17	<hr/> \$ (0.32)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - basic and diluted	<hr/> 46,482,793	<hr/> 7,138,149

The accompanying notes are an integral part of these consolidated financial statements.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Consolidated Statements of Changes in Equity

(Expressed in Canadian dollars)

	Share capital		Share-based payment reserve \$	Warrant reserve \$	Accumulated other comprehensive income (loss) \$	Accumulated Deficit \$	Total shareholders' equity (deficit) \$
	Number of shares #	Amount \$					
Balance September 30, 2015	7,061,263	7,552,726	-	-	(825,419)	(9,581,557)	(2,854,250)
Shares issued for debt	2,928,509	146,425	-	-	-	-	146,425
Shares issued in private placement	9,992,284	499,614	-	-	-	-	499,614
Share issue costs	-	(6,742)	-	-	-	-	(6,742)
Comprehensive income for the period	-	-	-	-	90,346	2,296,288	2,386,634
Balance September 30, 2016	19,982,056	8,192,023	-	-	(735,073)	(7,285,269)	171,681
Shares issued in share exchange with Angel shareholders in RTO	5,944,220	1,783,266	-	-	-	-	1,783,266
Warrants issued as consideration for the loan	-	-	-	275,170	-	-	275,170
Shares issued for cash	16,196,110	5,265,481	-	-	-	-	5,265,481
Share issue costs	-	(754,318)	-	226,932	-	-	(527,386)
Shares issued to SSR Mining Inc.	12,947,339	2,620,229	-	-	-	-	2,620,229
Stock options granted	-	-	875,340	-	-	-	875,340
Warrants exercised	9,992,284	999,228	-	-	-	-	999,228
Comprehensive income (loss) for the period	-	-	-	-	(28,515)	(7,733,181)	(7,761,696)
Balance, December 31, 2017	65,062,009	18,105,909	875,340	502,102	(763,588)	(15,018,450)	3,701,313

The accompanying notes are an integral part of these consolidated financial statements.

ABRAPLATA RESOURCE CORP.
(formerly Angel Bioventures Inc.)
Consolidated Statements of Cash Flows
(Expressed in Canadian dollars)

	Fifteen months ended December 31, 2017	Twelve months ended September 30, 2016
Operating activities		
Net (loss) income	\$ (7,733,181)	\$ 2,296,288
Items not involving cash		
Foreign exchange	21,846	(17,119)
Debt forgiveness	-	(2,965,694)
Interest paid by warrants	275,170	-
Impairment of mineral interests	27,378	-
Share-based payments	875,340	-
Listing transaction expense	1,817,436	-
Changes In non-cash working capital items		
Receivable	(60,823)	(7,636)
Accounts payable and accrued liabilities	1,056,948	416,650
Prepaid	(16,074)	1,621
Cash used in operating activities	(3,735,960)	(275,890)
Investing activities		
Cash acquired from RTO	475	-
Additions to mineral interests	(2,273,340)	(26,788)
Cash used in investing activities	(2,272,865)	(26,788)
Financing activities		
Cash provided by Meryllion Resources Corporation	-	81,302
Proceeds from shares issued, net of cash share issue costs	4,738,095	492,872
Proceeds from warrants exercised	999,228	-
Cash provided by financing activities	5,737,323	574,174
Effect of foreign exchange	(1,869)	23,922
Increase (decrease) in cash	(273,371)	295,418
Cash, beginning of period	295,594	176
Cash, end of period	\$ 22,223	\$ 295,594
Supplemental disclosure		
Interest paid	\$ -	\$ -
Income taxes paid	\$ -	\$ -
Warrants issued for interest	\$ 275,170	\$ -
Shares issued for debt	\$ -	\$ 146,425
Shares issued for mineral interests	\$ 2,620,229	\$ -
Shares issued for reverse takeover transaction	\$ 1,783,266	\$ -
Fair value of finders' warrants	\$ 226,932	\$ -

The accompanying notes are an integral part of these consolidated financial statements.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

1. NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS

AbraPlata Resource Corp. (formerly Angel Bioventures Inc.) (the "Company") was incorporated on August 31, 1993 under the Alberta Business Corporations Act. On September 30, 2015, the Company's incorporation jurisdiction was moved to British Columbia. The Company's registered office is located at Suite 303, 750 West Pender Street, Vancouver, BC, V6C 2T7.

On September 16, 2016, the Company signed a binding Letter of Intent ("LOI") with Huayra Minerals Corporation ("Huayra"). The LOI sets out the key terms of the proposed acquisition by the Company of 100% of the issued and outstanding securities of Huayra.

On November 15, 2016, the Company and its wholly-owned subsidiary, 1096494 BC Ltd., entered into a definitive merger agreement (the "Merger Agreement") with Huayra. Huayra is a mineral exploration and development company engaged in the acquisition, exploration and development of mineral resource properties in Argentina. Huayra has an agreement (the "SSRM Agreement") with SSR Mining Inc. ("SSRM") to acquire an indirect 100% interest in the Diablillos and Aguas Perdidas (previously known as "M-18") properties in Salta and Chubut Provinces, Argentina. Huayra also has rights in the Cerro Amarillo property in the Province of Mendoza, Argentina and the Samenta property in the Province of Salta, Argentina.

As per the terms of the Merger Agreement, Huayra and 1096494 BC Ltd. amalgamated (the "Amalgamation") and the amalgamated company became a wholly-owned subsidiary of the Company. Pursuant to the Amalgamation, the Company acquired all of the issued and outstanding Class A common shares of Huayra in exchange for a like number of common shares of the Company. The Amalgamation was an arm's length transaction and constituted a "reverse takeover" pursuant to the policies of the TSX Venture Exchange (the "Exchange").

The Amalgamation became effective on April 24, 2017. In this regard, the Company entered into an agreement with SSRM providing for the Company's assumption of all of Huayra's obligations under the SSRM Agreement.

As a condition precedent to the Amalgamation, the Company undertook the Concurrent Financing and raised \$2,863,099 in order for the Company to meet the initial listing requirements of the Exchange. The securities issued in the Concurrent Financing consist of 9,543,663 subscription receipts of the Company at a price of \$0.30 per share.

The Company also entered into an amended and restated merger agreement with 1096494 BC Ltd. and Huayra as of February 27, 2017 to replace and supersede the Merger Agreement and address certain corporate matters.

These consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at December 31, 2017, the Company has a working capital (deficiency) of \$(1,155,738) (September 30, 2016 - \$132,329) and has an accumulated deficit of \$15,018,450. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. Management is of the opinion that sufficient working capital will be obtained from external financing to meet the Company's liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These factors indicate the existence of a material uncertainty that may cast significant doubt upon the Company's ability to continue as a going concern. These consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

2. BASIS OF PREPARATION

Statement of Compliance

The consolidated financial statements for the fifteen months ended December 31, 2017 and twelve months ended September 30, 2016 were prepared in accordance with the International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board and interpretations of the International Financial Reporting Interpretations Committee in effect at December 31, 2017.

The Corporation changed its fiscal year-end from September 30 to December 31. Information included in the financial statements reflects the fiscal period consisting of the fifteen months ending December 31, 2017, as compared to the twelve months period ending September 30, 2016, and as a result, are not entirely comparable.

These consolidated financial statements were authorized for issue by the Board of Directors on April 30, 2018.

Basis of Measurement

The consolidated financial statements have been prepared on a historical cost basis. The consolidated financial statements are presented in Canadian dollars.

The accounting policies used in the preparation of these consolidated financial statements are the policies listed in the note 3.

Use of estimates and judgments

The preparation of consolidated financial statements in compliance with IFRS requires management to make certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

3. SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of consolidation

The consolidated financial statements include the accounts of the Company and the Company's wholly-owned subsidiaries Huayra Minerals Corp., Argentine subsidiaries AbraPlata Argentina S.A. (formerly Meryllion Argentina S.A.), Pacific Rim Mining Corporation Argentina S.A., and Minera Cerro Bayo S.A.; and British Virgin Island subsidiaries ABP Global Inc. (BVI) and ABP Diablillos Inc. (BVI). All inter-company transactions and balances have been eliminated.

(b) Critical accounting estimates and judgments

The preparation of these consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

(b) Critical accounting estimates and judgments (continued)

Critical accounting estimates

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the end of the reporting period, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the determination of environmental obligations, if any; the recoverability of mineral interests; and the inputs used in the Black-Scholes option pricing model to account for shares issued with trading restrictions.

Critical accounting judgments

Critical accounting judgments are accounting policies that have been identified as being complex or involving subjective judgments or assessments, which are discussed below.

Acquisitions

The Company's acquisition of all the outstanding shares of Pacific Rim Mining Corporation Argentina S.A., ABP Global Inc. (BVI) and ABP Diablillos Inc. (BVI) (together, the "SSRM subsidiaries", see note 7(a)) has been determined to be an asset acquisition as the SSRM subsidiaries do not meet the definition of a business under IFRS 3 – Business Combinations. As a result, the acquisition of the SSRM subsidiaries has been accounted for as an asset acquisition, whereby all of the assets acquired and liabilities assumed are recorded at fair value.

The Company's acquisition of all the outstanding shares of Minera Cerro Bayo S.A. ("MCB SA", see note 7(a)) has been determined to be an asset acquisition as MCB SA does not meet the definition of a business under IFRS 3 – Business Combinations. As a result, the acquisition of MCB SA has been accounted for as an asset acquisition, whereby all of the assets acquired and liabilities assumed are recorded at fair value.

Functional currency

In accordance with IAS 21 "*The Effects of Changes in Foreign Exchange Rates*", management determined that the functional currency of AbraPlata Argentina S.A. (former Meryllion Argentina S.A.), Pacific Rim Mining Corporation Argentina S.A., and Minera Cerro Bayo S.A. is Argentine Peso. The functional currency of ABP Global Inc. (BVI) and ABP Diablillos Inc. (BVI) is the US dollar. The functional currency of AbraPlata Resource corp. and Huayra Minerals Corp. is Canadian dollar.

Impairment of mineral interests

The application of the Company's accounting policy for exploration and evaluation expenditure and impairment of the capitalized expenditures requires judgment in determining whether it is likely that future economic benefits will flow to the Company, which may be based on assumptions about future events or circumstances. Estimates and assumptions made may change if new information becomes available. If, after expenditure is capitalized, information becomes available suggesting that the recovery of expenditure is unlikely, the amount capitalized is written off in profit or loss in the year the new information becomes available.

Going concern risk assessment

The assessment of the Company's ability to continue as a going concern involves significant judgment. Refer to our discussion in Note 1.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

(c) Provisions

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

(d) Foreign currency translation

Functional and presentation currency

Items included in the financial statements of the Company and its subsidiary are measured using the currency of the primary economic environment in which the entity operates (the functional currency). These consolidated financial statements are presented in Canadian Dollars. The Company's presentation currency is the Canadian dollar and the Company and its subsidiaries' functional currencies are summarized in note 3(b).

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.

Exchange differences arising on the translation of monetary items or on settlement of monetary items are recognized in profit or loss in the consolidated statement of comprehensive (income) loss in the period in which they arise. Exchange differences arising on the translation of non-monetary items are recognized in other comprehensive (income) loss in the consolidated statement of comprehensive (income) loss to the extent that gains and losses arising on those non-monetary items are also recognized in other comprehensive (income) loss. Where the non-monetary gain or loss is recognized in profit or loss, the exchange component is also recognized in profit or loss.

Parent and Subsidiary Companies

The financial position and results of operations whose functional currency is different from the presentation currency are translated as follows:

- assets and liabilities are translated at period-end exchange rates prevailing at that reporting date; and
- income and expenses are translated at the average exchange rates for the period.

Exchange differences are transferred directly to the consolidated statement of comprehensive (income) loss and are included in a separate component of equity titled "Accumulated other comprehensive income or loss – currency translation adjustment". These differences are recognized in profit or loss in the period in which the operation is disposed of.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

(e) Evaluation and exploration expenses

Evaluation and exploration expenses are comprised of costs that are directly attributable to:

- researching and analyzing existing exploration data;
- conducting geological studies, exploratory drilling and sampling;
- examining and testing extraction and treatment methods; and
- activities in relation to evaluating the technical feasibility and commercial viability of extracting a mineral resource.

All exploration and evaluation expenditures are expensed until properties are determined to contain economically viable reserves. When economically viable reserves have been determined, technical feasibility has been determined and the decision to proceed with development has been approved, the subsequent costs incurred for the development of that project are capitalized as mining properties, a component of property, plant and equipment.

Development expenditures are net of the proceeds of the sale of ore extracted during the development phase. Interest on borrowings related to the construction and development of assets are capitalized until substantially all the activities required to make the asset ready for its intended use are complete.

The costs of removing overburden to access ore are capitalized as pre-production stripping costs and classified as mineral interests.

(f) Mineral interests

Mineral interests include any costs relating to the acquisition and claim maintenance of mineral properties, including option payments and annual fees to maintain the property in good standing. When economically viable reserves have been determined, technical feasibility has been determined and the decision to proceed with development has been approved by the Board of Directors, the capitalized mineral interests for that project are capitalized as mining properties, a component of property, plant and equipment. Upon determination and the decision to proceed with development of a mineral interest, the mineral interest is tested for impairment and then reclassified from mineral interests to mining properties, net of any impairment losses.

The Company assesses its capitalized mineral interests for indications of impairment on a regular basis and when events and circumstances indicate a risk of impairment. A mineral interest is written down or written off when the Company determines that an impairment of value has occurred or when exploration results indicate that no further work is warranted.

Although the Company has taken steps to verify title to mineral properties in which it has an interest, these procedures do not guarantee the Company's title. Such properties may be subject to prior agreements or transfers, or title may be affected by undetected defects.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

(g) Impairment of long-lived assets

Long-lived assets are assessed for impairment at each reporting date. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less cost to sell and value in use. Fair value is determined as the amount that would be obtained from the sale of the asset in an arm's length transaction between knowledgeable and willing parties. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash generating units). These are typically individual mines or development projects.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but to an amount that does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

(h) Loss (earnings) per share

The basic loss (earnings) per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. The diluted loss per share reflects the potential dilution of common share equivalents, such as outstanding stock options and share purchase warrants, in the weighted average number of common shares outstanding during the period if dilutive. The Company uses the treasury stock method of calculating fully diluted per share amounts whereby any proceeds from the exercise of stock options or other dilutive instruments are assumed to be used to purchase common shares at the average market price during the year. Diluted loss (earnings) per share has not been presented separately as the outstanding options are anti-dilutive for each period presented.

(i) Income taxes

Income tax expense comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity.

Current tax

Current tax expense is the expected tax payable on taxable income for the year, using tax rates enacted or substantively enacted at period end, adjusted for amendments to tax payable with regards to previous years.

Deferred tax

Deferred tax is accounted for using the liability method, providing for the tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and their respective tax bases.

A deferred tax liability is recognized for all taxable temporary differences except where the deferred income tax liability arises from the initial recognition of goodwill, or the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss, and in respect of taxable temporary differences associated with investments in subsidiaries, where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

(i) Income taxes (continued)

A deferred income tax asset is recognized for all deductible temporary differences, carry-forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry-forward of unused tax credits and losses can be utilized, except where the deferred income tax asset related to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss. In respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

Deferred tax is measured on an undiscounted basis using the tax rates that are expected to apply in the period when the liability is settled or the asset is realized, based on tax rates and tax laws enacted or substantively enacted at the statement of financial position date. Deferred tax assets and liabilities are offset when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

(j) Share-based compensation

The Company grants share-based awards to certain officers, employees, directors and other eligible persons. For equity-settled awards, the fair value is charged to profit or loss and credited to the related reserve account, on a straight-line basis over the vesting period, after adjusting for the estimated number of awards that are expected to vest.

The fair value of the equity-settled awards is determined at the date of the grant. In calculating fair value, no account is taken of any vesting conditions, other than conditions linked to the price of the shares of the Company. The fair value is determined by using the Black-Scholes option pricing model.

At each statement of financial position date, the cumulative expense representing the extent to which the vesting period has expired and management's best estimate of the awards that are ultimately expected to vest is computed. The movement in cumulative expense is recognised in profit or loss with a corresponding entry against the related reserve. No expense is recognised for awards that do not ultimately vest. The amount remains in the related reserve for stock options which expire unexercised.

Where equity instruments are granted to non-employees, they are recorded at the fair value of the goods or services received in profit or loss, unless they are related to the issuance of shares. Amounts related to the issuance of shares are recorded as a reduction of share capital. When the value of goods or services received in exchange for the share-based payment cannot be reliably estimated, the fair value is measured by use of a valuation model. The fair value of stock options granted to non-employees is re-measured at the earlier of each financial reporting or vesting date, and any adjustment is charged or credited to operations upon re-measurement.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

(k) Share capital

Common shares

Common shares are classified as equity. Transaction costs directly attributable to the issue of common shares and share options are recognized as a deduction from equity, net of any tax effects.

Equity units

The Company has adopted a residual value method with respect to the measurement of shares and warrants issued as private placement equity units. The residual value method first allocates value to the more easily measurable component based on fair value and then the residual value, if any, to the less easily measurable component. The fair value of the common shares issued in the private placements are determined to be the more easily measurable component and are valued at their fair value, as determined by the closing quoted bid price on the announcement date. The balance, if any, is allocated to the attached warrants. The value attributed to the warrants is recorded as an equity reserve. If the warrants are exercised, the value attributable to the warrants is transferred to share capital.

(l) Financial instruments

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership.

All of the Company's financial instruments are classified into one of two categories: loans-and-receivables and other-financial-liabilities. All financial instruments are initially measured in the consolidated statement of financial position at fair value. Subsequent measurement and changes in fair value will depend on their initial classification. Loans-and-receivables and other-financial-liabilities are measured at amortized cost.

The Company does not use derivative instruments or hedges to manage risks. Transaction costs related to the Company's financial instruments will be added to their carrying amounts.

Financial assets and liabilities are offset and the net amount reported in the consolidated statement of financial position when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously.

Impairment of financial assets

The Company assesses at each statement of financial position date whether there is objective evidence that a financial asset is impaired. Objective evidence of impairment could include the following:

- Significant financial difficulty of the issuer or counterparty;
- Default or delinquency in interest or principal payments; or
- It has become probable that the borrower will enter bankruptcy or financial reorganization.

Where impairment has occurred, the cumulative loss is recognized in profit or loss.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

(m) Rehabilitation obligations

The Company recognizes the fair value of a legal or constructive liability for a rehabilitation obligation in the year in which it is incurred and when a reasonable estimate of fair value can be made. The carrying amount of the related long-lived asset is increased by the same amount as the liability. Changes in the liability for an asset retirement obligation due to the passage of time will be measured by applying an interest method of allocation. The amount will be recognized as an increase in the liability and an accretion expense in profit or loss. Changes resulting from revisions to the timing or the amount of the original estimate of undiscounted cash flows are recognized as an increase or a decrease to the carrying amount of the liability and the related long-lived asset. The Company does not have significant rehabilitation obligations.

(n) New Standards Not Yet Effective

The following is an overview of new accounting standards that the Company will be required to adopt in future years. The Company does not expect to adopt any of these standards before their effective dates and expects no significant effect on the Company's consolidated financial statements when adopted.

- IFRS 9 Financial Instruments - This standard provides added guidance on the classification and measurement of financial liabilities. The standard is effective for annual periods beginning on or after January 1, 2018.
- IFRS 2 Classification and Measurement of Share-based Payment Transactions – This standard was issued in June 2016. The amendments provide requirements on accounting for the effect of vesting and non-vesting conditions on the measurement of cash settled share-based payments, share-based transactions with a net settlement feature for withholding tax obligations and a modification to the terms and conditions of a share-based payment that changes the classification of the transactions from cash-settled to equity-settled. This standard is effective for reporting periods beginning on or after January 1, 2018.
- IFRS 16 Leases - This standard was issued in January 2016 and specifies how an IFRS reporter will recognize, measure, present and disclose leases. The standard provides a single lessee accounting model, requiring lessees to recognize assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value. Lessors continue to classify leases as operating or finance, with IFRS 16's approach to lessor accounting substantially unchanged from its predecessor, IAS 17. This standard is effective for reporting periods beginning on or after January 1, 2019.

4. FINANCIAL INSTRUMENTS

(a) Designation and valuation of financial instruments

The Company has designated its cash and receivable as loans-and-receivables, and accounts payable and accrued liabilities as other-financial-liabilities.

The carrying values of cash, receivable, and accounts payable and accrued liabilities approximate their fair values.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

4. FINANCIAL INSTRUMENTS (continued)

(a) Designation and valuation of financial instruments (continued)

The Company's financial instruments that are measured subsequent to initial recognition at fair value, are grouped into Level 1 to 3 based on the degree to which the inputs used to determine the fair value are observable:

- Level 1 of the fair value hierarchy includes unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 of the hierarchy includes inputs that are observable for the asset or liability, either directly or indirectly; and
- Level 3 includes inputs for the asset or liability that are not based on observable market data.

The Company does not have any financial instruments included in Level 1, 2 and 3.

(b) Financial risks

The Company may be exposed to risks of varying degrees of significance which could affect its ability to achieve its strategic objectives. The Company manages risks to minimize potential losses. The main objective of the Company's risk management process is to ensure that the risks are properly identified and that the capital base is adequate in relation to those risks. The Company's risk exposure and the impact on the Company's financial instruments are summarized below:

Credit risk

Credit risk is the risk of potential loss to the Company if the counterparty to a financial instrument fails to meet its contractual obligations.

The Company is exposed to credit risk with respect to its cash and receivable. The Company's maximum exposure to credit risk is their carrying amounts disclosed in the consolidated statement of financial position. Credit risk associated with cash is minimized by placing these instruments with major Canadian financial institutions with strong investment-grade ratings as determined by a primary ratings agency. Credit risk associated with accounts receivable is minimal as the majority of the balance is owing from Canada Revenue Agency.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.

At December 31, 2017, the Company had a cash balance of \$22,223 to settle current liabilities of \$1,264,839. All of the Company's financial liabilities have contractual maturities of less than 30 days and are subject to normal trade terms.

The Company intends to finance future requirements from share issuances, the exercise of options and/or warrants, debt or other sources. There can be no certainty of the Company's ability to raise additional financing through these means.

Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in market factors. Market risk comprises three types of risk: price risk, interest rate risk and currency risk.

Price risk

Price risk is the risk that the fair value of future cash flows of the Company's financial instruments will fluctuate because of changes in market prices. The Company is not exposed to price risks.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

4. FINANCIAL INSTRUMENTS (continued)

(b) Financial risks (continued)

Interest rate risk

Interest rate risk is the risk that the fair values and future cash flows of the Company will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk to the extent that the cash and cash equivalents, if any, maintained at financial institutions is subject to a floating rate of interest. The interest rate risk on cash is not considered significant.

Currency risk

Currency risk is the risk that the fair values or future cash flows of the Company's financial instruments will fluctuate because of changes in foreign currency exchange rates. The Company is exposed to currency risk through financial assets and liabilities denominated in currencies other than the Canadian dollar, the Company's presentation currency. The Company's financial instruments denominated in currencies that are not the Canadian dollar as at December 31, 2017 are as follows:

	<u>US\$</u>	<u>Argentine Peso</u>	<u>C\$ equivalent</u>
Cash	356	7,966	892
Accounts payable and accrued liabilities	39,200	3,502,828	284,889

The Company's sensitivity analysis suggests that a 10% depreciation or appreciation of the foreign currencies against the Canadian dollar would have resulted in an approximate \$28,400 decrease or increase in the Company's other comprehensive income or loss.

As at December 31, 2017, US dollar amounts have been translated at a rate of C\$1.2545 per US dollar and Argentine peso amounts have been translated at C\$0.06729 per Argentine peso.

5. REVERSE TAKE OVER AND LISTING TRANSACTION

On April 24, 2017 the Company completed a reverse takeover transaction ("RTO"). Concurrent with the closing of the reverse take over transaction the Company changed its name from Angel Bioventures Inc. ("Angel") to AbraPlata Resource Corp. On April 24, 2017, Angel acquired 100% ownership of Huayra Minerals Corp. ("Huayra") by issuing 19,982,056 of its common shares. For accounting purposes, the acquisition is considered to be outside the scope of IFRS 3 Business Combinations since Angel, prior to the RTO, did not constitute a business. The RTO is accounted for in accordance with IFRS 2 Share-based Payments whereby Huayra is deemed to have issued shares in exchange for the net assets of Angel together with its TSX-V listing status at the fair value of the consideration received by Huayra. The accounting for the RTO resulted in the following:

- (i) The consolidated financial statements of the combined entities are issued under the legal parent, Angel, but are considered a continuation of the financial statements of the legal subsidiary, Huayra.
- (ii) Since Huayra is deemed to be the acquirer for accounting purposes, its assets and liabilities are included in the consolidated financial statements at their historical carrying values.

The Company cannot identify specifically some or all of the goods or services received in return for the allocation of the shares. The value in excess of the net identifiable assets or obligations of Angel acquired on closing was expensed in the consolidated statement of comprehensive loss as a listing transaction expense.

The listing transaction expense in the amount of \$2,268,688 is comprised of the fair value of common shares of the Company retained by the former shareholders of Angel, the assumption of a net liabilities over assets as well as other direct expenses of the transaction.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

5. REVERSE TAKE OVER AND LISTING TRANSACTION (continued)

The fair value of the common shares issued was \$1,783,266, based on the price of shares issued in the concurrent private placement of \$0.30 per share.

The listing transaction expense is summarized as follows:

	Number	Amount
Consideration:		
Shares issued	5,944,220	\$ 1,783,266
Net liabilities over assets:		
Trade payables and accrued liabilities		36,990
Cash		(475)
Receivables		(623)
Prepaid expenses		(1,722)
		34,170
Legal and other transaction costs		451,252
Total listing transaction expense		\$ 2,268,688

6. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development and exploration of its mineral properties and to maintain a flexible capital structure, which optimizes the costs of capital to an acceptable risk.

The Company depends on external financing to fund its activities and there can be no guarantee that external financing will be available at terms acceptable to the Company. The Company does not believe its current working capital is sufficient to maintain its core operations for the next twelve months, and additional funding will be required by the Company to complete its strategic objectives and continue as a going concern. There is no certainty that additional financing at terms that are acceptable to the Company will be available. The capital structure of the Company currently consists of common shares. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new debt, new shares or warrants.

Management reviews its capital management approach on a regular basis. There were no changes in the Company's approach to capital management. Pursuant to the second amended and restated share purchase agreement dated March 21, 2017, SSRM has the right to maintain a free carried 19.9% equity interest in the Company until the completion of a qualified financing and to elect, after the completion of a qualified financing, to participate in future equity financings to maintain its ownership level in the Company for as long as SSRM continues to hold not less than ten percent of the then issued and outstanding shares of the Company on a non-diluted basis. Subsequent to the period ended December 31, 2017 the Company completed a qualified financing and is not obligated to maintain SSRM's free carried equity interest.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

7. MINERAL INTERESTS

Through the Company's wholly-owned subsidiaries, the Company controls exploration concessions in Argentina classified by the Company into the Diablillos Project, Cerro Amarillo Project and Samenta Project. All acquisition costs and option payments related to these exploration concessions are capitalized as mineral interests and are incurred in US dollars and translated to Canadian dollar, the presentation currency for the Company.

(a) Diablillos property

- (1) On November 1, 2016, the Company closed a Share Purchase Agreement dated August 23, 2016, as amended and restated on March 21, 2017, with SSRM and Fitzcarraldo Ventures Inc. pursuant to which Huayra acquired from SSRM all of the issued and outstanding shares of Pacific Rim Mining Corporation Argentina S.A., ABP Global Inc. (BVI) and ABP Diablillos Inc. (BVI) (together, the "SSRM subsidiaries"). Through the acquisition of the SSRM subsidiaries, the Company acquired certain exploration concessions in Salta and Chubut Provinces, Argentina (the "Diablillos Concessions" and the "M-18 Concessions").

Cash consideration payable to SSRM consists of the following:

- US\$300,000 on closing; this amount to be increased by an amount equal to the US dollar equivalent of the amount of Argentine Pesos deposited in entity purchased by the Company (paid)
- US\$300,000 on or before February 15, 2017 (as amended) (paid)
- US\$500,000 on 180th day after closing (paid)
- US\$50,000 to be paid on or before January 12, 2018 (as amended) (paid subsequent to the period end)
- US\$5,000,000 to be paid on the earlier of:
 - The 3rd anniversary of closing
 - The date on which the Company obtains a feasibility study in respect of all or any part of the property covered by the Diablillos Concessions
- US \$7,000,000 to be paid on the earlier of:
 - The 5th anniversary of closing
 - The date on which construction of mining facilities commences on all or any part of the property covered by the Diablillos Concessions

Equity consideration consists of Class B common shares of the Company (11,294,609 shares issued, see note 9(b)) which automatically converted into a number of Huayra Class A Shares that, upon the completion of the RTO, resulted in SSRM holding common shares of the Company representing 19.9% of the Company's then outstanding common shares. The agreement provides SSRM an anti-dilution right to maintain 19.9% equity interest in the capital of the Company until the Company completes a qualified financing of a minimum of U.S. \$5,000,000.

The royalty consideration payable to SSRM consists of a 1% net smelter returns royalty. SSRM is entitled to receive advance royalty payments totalling US\$1,000,000 over 4 years as follows:

- US\$250,000 on November 1, 2017 (paid);
- US\$250,000 on November 1, 2018;
- US\$250,000 on November 1, 2019;
- US\$250,000 on November 1, 2020.

These advance royalty payments will be deducted and set off against the first \$1,000,000 of net smelter returns royalty payments otherwise payable in respect of the Diablillos Concessions.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

7. MINERAL INTERESTS (continued)

(a) Diablillos property (continued)

As security for the above obligations, the Company has pledged to SSRM all the shares the Company acquired in the two entities which hold the interests to the Diablillos Concessions and the M-18 Concessions.

- (2) On August 30, 2017 the Company signed an agreement to acquire all of the issued and outstanding shares of Minera Cerro Bayo S.A. ("Cerro Bayo"), a privately held Argentine company. Cerro Bayo owns certain mineral rights that, as a result of a long-standing border dispute between two neighboring provinces in northwestern Argentina, overlap and potentially conflict with the Company's mineral rights to its Diablillos Ag-Au project. The acquisition of the potentially conflicting mineral rights through the acquisition of Cerro Bayo means that the Company will retain its title to the Diablillos Ag-Au project regardless of the ultimate outcome of the provincial border dispute.

Cash and equity consideration payable under the agreement is as follows:

- US\$225,000 upon closing (paid)
- US\$175,000 on or before February 28, 2018 (paid subsequent to the period end)
- US\$175,000 and 150,000 common shares on or before August 30, 2018
- US\$175,000 and 150,000 common shares on or before February 28, 2019
- US\$150,000 and 200,000 common shares on or before August 30, 2019
- US\$250,000 on or before February 29, 2020
- US\$350,000 on or before August 30, 2020
- US\$825,000 to be paid on the earlier of February 28, 2021 or the date on which the Company has obtained a Diablillos Feasibility Study as defined in the SSRM agreement dated August 23, 2016.
- US\$1,000,000 is to be paid on the earlier of the date of commencement of mine construction at the Diablillos project or November 1, 2021.

(b) Samenta property

During the year ended September 30, 2015, AbraPlata Argentina S.A. ("APA SA") acquired the option to purchase the Samenta Cu-Mo porphyry prospect located in the province of Salta in northwestern Argentina. SPA SA signed exploration-with-option-to-purchase agreements, which were amended in July 2016, on two separate but contiguous claim groups, Cerro Samenta Norte and Cerro Samenta Sur, comprising the Samenta Project.

Cash consideration payable per the agreement is as follows:

- US\$30,000 upon completion of the due diligence (paid)
- US\$50,000 in February 2017 (paid)
- US\$70,000 in August 2017 (paid)
- US\$90,000 in August 2018
- US\$130,000 in August 2019.

An exercise fee of US\$4,230,000 will be due at the end of August 2020. The underlying owners are also entitled to a 1.5% NSR royalty of which 0.5% can be purchased back for US\$1,000,000.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

7. MINERAL INTERESTS (continued)

(c) Cerro Amarillo property

For the Cerro Amarillo Project, the Company is awaiting the ratification of the appropriate permits to undertake, subject to financing, a stage one drilling campaign. On December 1, 2014, the Company announced that during the congressional deliberations that took place in November 2014, it was determined that any decision regarding the ratification of the drill permit should be delayed pending the completion of an inventory of glaciers in or near the project to be conducted by *Instituto Argentino de Nivología Glaciología y Ciencias Ambientales* ("IANIGLA"), the federal body charged with conducting the inventory under the Protection of Glaciers Law 26.639. IANIGLA has already begun the inventory, which was expected to be completed in 2015.

On July 14, 2016, APA SA, signed an agreement for the right to purchase the Cerro Amarillo property located in the province of Mendoza in Argentina. This agreement is a replacement agreement to the one that was entered into in 2010.

The Company made the following payments:

- US\$25,000 in October 2016, deferred to May 2017 (paid)
- and will pay US\$25,000 annually every November, starting in November 2017, until the earlier of the ratification of appropriate permits or the receipt of exploration permits given in accordance with the legislature of the province of Mendoza (the "Notification Date"). The Company will then make a series of installments in total of US\$875,000 over 48-month period from the Notification Date.

An exercise fee of US\$2,500,000 will be due by the end of 60 months period from the Notification Date. The underlying owners are also entitled to a 1% NSR royalty which can be purchased back for US\$3,000,000.

Due to uncertainty of the timing for the completion of the glaciers inventory and the ratification of the permits, the Company wrote down the Cerro Amarillo property by \$27,378 to \$1 during the period ended December 31, 2017.

The changes to the Company's mineral interests were as follows:

	Diablillos, Argentina	Cerro Amarillo, Argentina	Samenta, Argentina	Total
Balance as at September 30, 2015	\$ -	\$ 1	\$ 40,182	\$ 40,183
Foreign exchange translation	-	-	(831)	(831)
Balance as at September 30, 2016	-	1	39,351	39,352
Additions, cash	2,084,552	33,860	154,928	2,273,340
Additions, shares	2,620,229	-	-	2,620,229
Foreign exchange translation	-	(6,482)	(42,010)	(48,492)
Impairment	-	(27,378)	-	(27,378)
Balance as at December 31, 2017	\$ 4,704,781	\$ 1	\$ 152,269	\$4,857,051

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

8. EVALUATION AND EXPLORATION EXPENSES

The Company's exploration expenses for the fifteen months ended December 31, 2017 and twelve months ended September 30, 2016 are as follows:

	Fifteen months ended December 31, 2017	Twelve months ended September 30, 2016
Cerro Amarillo		
Administration	\$ -	\$ 45,376
Camp Costs	2,407	6,368
Legal and regulatory fee	7,313	-
Travel and Transport	2,465	77
Other	-	12,817
Total Cerro Amarillo	\$ 12,185	\$ 64,638
Samenta		
Administration	\$ -	\$ 72,158
Legal and regulatory fee	27,654	-
Travel and Transport	-	137
Other	-	30,494
Total Samenta	\$ 27,654	\$ 102,789
Diablillos		
Administration	\$ 13,021	\$ -
Camp Costs	167,050	-
Engineering and geology	192,961	-
Drilling	968,567	-
Legal and regulatory fee	315,089	-
Personnel Costs	339,991	-
Report	115,242	-
Travel and Transport	217,452	11,830
Other	23,649	72,942
Total Diablillos	\$ 2,353,022	\$ 84,772
Total exploration	\$ 2,392,861	\$ 252,199

9. SHARE CAPITAL**(a) Authorized**

Authorized: Unlimited common shares without par value. Unlimited first preferred shares without par value. Unlimited second preferred shares without par value.

(b) Issued and outstanding

Pursuant to the Merger Agreement, 21,284,381 shares were placed in escrow, 2,128,436 of which were released on April 24, 2017. The rest will be released from escrow every six months after the initial release at a rate of 15%. At December 31, 2017, 15,963,290 shares remain in escrow (September 30, 2016 – nil).

Also, during the period ended December 31, 2017, the Company had shares held in escrow under the pooling agreement, 2,077,336 of which were released during the period. At December 31, 2017, 1,038,668 shares remain in escrow (September 30, 2016 – nil).

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

9. SHARE CAPITAL (continued)

(b) Issued and outstanding (continued)

On August 4, 2017 the Company closed, on a non-brokered basis, an offering of 4,066,480 common shares of the Company by way of a private placement at a price of \$0.40 per share for total gross proceeds of \$1,626,592. In connection with the financing, the Company paid to certain arm's length parties a finder's fee comprised of cash fee of \$127,097 and share purchase warrants exercisable to acquire up to 317,742 common shares of the Company. The warrants are exercisable for a period of one year from the date of issuance at a price of (i) \$0.40 per common share during the first six months after a finder warrant is issued, and (ii) \$0.60 per common share for the following six months thereafter. Fair value of the finder warrants was estimated as \$64,322. In addition, the Company incurred share issue costs of \$49,115.

Pursuant to SSR Mining Inc.'s (formerly Silver Standard Resources Inc., "SSRM") contractual anti-dilution right to maintain a 19.9% equity interest in the capital of the Company (note 7(a)), under the second amended and restated share purchase agreement dated March 21, 2017 (the "SSRM Agreement"), 1,010,274 common shares were issued to SSRM. The fair value of these shares were determined to be \$404,110, based on the price of the shares issued in the concurrent private placement of \$0.40 per share, when the original 19.9% equity consideration was issued.

On May 16, 2017, the Company completed, on a non-brokered basis, an offering of 2,585,967 common shares of the Company by way of a private placement at a price of \$0.30 per share for total gross proceeds of \$775,790. On April 24, 2017, the Company completed a Concurrent Financing of 9,543,663 common shares of the Company at a price of \$0.30 for gross proceeds of \$2,863,099. In connection with these offerings, the Company paid \$351,174 in share issue costs and granted finder warrants exercisable to acquire up to 927,706 common shares of the Company. The finder warrants will be exercisable for a period of one year from the date of issuance at a price of (i) \$0.30 per common share during the first six months after a finder warrant is issued, and (ii) \$0.50 per common share for the following six months thereafter. Fair value of the finder warrants was estimated as \$162,610.

Pursuant to the anti-dilution right in the SSRM Agreement, 642,456 common shares were issued to SSRM. The fair value of these shares were determined to be \$192,736 based on the price of the shares issued in the concurrent private placement of \$0.30 per share, when the original 19.9% equity consideration was issued.

On April 24, 2017, the Company completed the RTO and issued 5,944,220 shares with a fair value of \$1,783,266 (note 5).

On April 24, 2017, the Company issued 11,294,609 shares pursuant to the SSRM Agreement for the acquisition of the Diablillos property. The shares are held in escrow and released over 3 years. The fair value of these shares were estimated to be \$2,023,384 based on the price of the shares issued in the concurrent private placement of \$0.30 per share, discounted by the put option, calculated using the Black-Scholes option-pricing model, for the length of the hold period.

On April 24, 2017, 9,992,284 warrants were exercised at an exercise price of \$0.10 and 9,992,284 shares were issued.

During the twelve months ended September 30, 2016 the Company closed a non-brokered private placement of 9,992,284 units of the Company at a price of \$0.05 per unit for gross proceeds of \$499,614. Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share for 24 months from the closing of the private placement at a price of \$0.10 per common share. In connection with the private placement, the Company paid \$6,742 in legal fees as share issue costs.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

9. SHARE CAPITAL (continued)**(c) Stock options**

On June 7, 2017 the Company granted 2,350,000 incentive stock options to directors, officers and consultants of the Company. The stock options have an exercise price of \$0.63 per share and are exercisable for a period of five years from the date of grant. The stock options vest 25% immediately, 25% after six months, 25% after twelve months and 25% after eighteen months. The fair value of the stock options was determined to be \$1,243,032 on grant date using the Black-Scholes option pricing model with the following assumptions: 5 years expected life; share price at the grant date of \$0.62; 107% volatility; risk free interest rate of 0.88%; and a dividend yield of 0%.

On November 15, 2017 the Company granted 900,000 stock options. The stock options have an exercise price of \$0.25 per share and are exercisable for a period of five years from the date of grant. The stock options vest 25% immediately, and the balance vests in three equal semi-annual installments commencing on the six months anniversary of the date of grant and continuing every six months thereafter until the options are fully vested. The fair value of the stock options was determined to be \$169,321 on grant date using the Black-Scholes option pricing model with the following assumptions: 5 years expected life; share price at the grant date of \$0.25; 105% volatility; risk free interest rate of 1.58%; and a dividend yield of 0%.

Expected volatility was estimated based on similar-sized entities in the industry.

During the fifteen months ended December 31, 2017 the company recorded \$875,340 (2016 - \$Nil) in share-based payments related to the stock options.

The movement in the Company's share options for the fifteen months ended December 31, 2017 are as follows:

	Number of options	Weighted average exercise price
Outstanding, September 30, 2015 and 2016	-	\$ -
Granted	3,250,000	0.52
Forfeited	(87,500)	(0.63)
Outstanding, December 31, 2017	3,162,500	\$ 0.52
Exercisable, December 31, 2017	1,375,000	\$ 0.57

At December 31, 2017, the Company has the following stock options outstanding:

Number of options outstanding	Number of options exercisable	Exercise Price	Expiry Date
2,262,500	1,150,000	\$0.63	June 7, 2022
900,000	225,000	\$0.25	November 22, 2022

At December 31, 2017, the weighted average remaining contractual life of options outstanding was 4.57 years.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

9. SHARE CAPITAL (continued)**(d) Warrants**

The movement in the Company's warrants for the fifteen months ended December 31, 2017 and twelve months ended September 30, 2016 are as follows:

	Number of warrants	Weighted average exercise price
Outstanding, September 30, 2015	-	\$ -
Issued	9,992,284	0.10
Outstanding, September 30, 2016	9,992,284	0.10
Issued	2,845,448	0.28
Exercised	(9,992,284)	(0.10)
Expired	(1,600,000)	(0.25)
Outstanding, December 31, 2017	1,245,448	\$ 0.33

At December 31, 2017, the Company has the following warrants outstanding:

Number of warrants	Exercise Price	Expiry Date
763,493*	\$0.30 first six months \$0.50 second six months	April 24, 2018
164,213	\$0.30 first six months \$0.50 second six months	May 16, 2018
317,742	\$0.40 first six months \$0.60 second six months	August 4, 2018

* expired unexercised subsequent to the period

At December 31, 2017, the weighted average remaining contractual life of warrants outstanding was 0.39 years.

During the period, the Company entered into a loan agreement for aggregate proceeds of \$400,000, which was non-interest bearing and was repaid in full by December 31, 2017. Pursuant to the loan agreement the Company issued 1,600,000 share purchase warrants, which entitles the holder to purchase one common share of the Company at a price of \$0.25 per share and are exercisable until October 31, 2017. The warrants were valued at \$275,170 using the Black-Scholes Option Pricing Model with the following assumptions: share price on vesting date of \$0.40, risk-free rate of 0.72%, dividend rate of 0%, expected life of 0.52 years, and volatility of 81%.

The 1,245,448 finders' warrants were valued at \$226,932 using the Black-Scholes Option Pricing Model with the following assumptions: share price on vesting date of between \$0.30 and \$0.48, risk-free rate of between 0.69% and 1.23%, dividend rate of 0%, expected life of one year, and volatility of between 64% and 108%.

Expected volatility was estimated based on similar-sized entities in the industry.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

10. RELATED PARTY TRANSACTIONS

Key Management includes personnel having the authority and responsibility for planning, directing and controlling the Company and includes the directors and current executive officers. Expenses incurred for Key Management compensation are summarized as:

	Fifteen months ended December 31, 2017	Twelve months ended September 30, 2016
Directors' fees	\$ 514,462 ⁽¹⁾	\$ 81,676
Administration	110,000	-
Consulting fees	57,764	84,312
Share-based payments	648,950	-
	<u>\$ 1,331,176</u>	<u>\$ 165,988</u>

⁽¹⁾ 50% of these fees were deferred until the completion of qualified financing of US\$5 million.

As at December 31, 2017 \$377,727 (2016 - \$11,172) was payable to directors and officers of the Company, and \$21,603 (2016 - \$5,250) to a management company of which employees are officers of the Company. These amounts are unsecured, non-interest bearing and have no specific terms of repayment.

During the twelve months ended September 30, 2016 three directors of the Company advanced non-interest-bearing loans totaling US\$27,894. During the period ended September 30, 2016 debt in the amount of \$180,210 was settled by issuing shares of the Company.

11. SEGMENTED INFORMATION

The Company has one operating segment. Its exploration and evaluation properties are located in Argentina.

12. COMMITMENTS

Effective June 1, 2017, the Company has agreed to pay a monthly fee of \$10,000 to the management company for provision of management and administrative services. The agreement may be terminated by the Company with 60 days' written notice.

As at December 31, 2017, the Company has mineral interest commitments at its Diablillos, Cerro Amarillo and Samenta projects in the form of option payments. The Company is in the process of conducting a strategic review of its properties under option and although as at the current date the Company had the commitments shown in the table below, some of these commitments could be reduced or eliminated completely pending the outcome of the strategic review. The Company also has operating expenses in Buenos Aires and in Vancouver.

	2018	2019	2020	2021	After 2022
Mineral interest commitments					
Cerro Amarillo	\$ 31,363	\$ 31,363	\$ 31,363	\$ 31,363	\$ 3,136,250
Samenta	112,905	163,085	5,306,535	-	-
Diablillos	815,425	6,993,838	1,066,325	11,070,963	-
Total mineral interest commitments	959,693	7,188,286	6,404,223	11,102,326	3,136,250
Minimum office rental payments in Argentina	40,646	40,646	27,097	-	-
Total commitments	\$1,000,339	\$ 7,228,932	\$ 6,431,320	\$ 11,102,326	\$ 3,136,250

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

13. INCOME TAX

The provision for income taxes for the fifteen months ended December 31, 2017 and the twelve months ended September 30, 2016 differs from the amount calculated using the Canadian federal and provincial statutory income tax rates of 26.0% as follows:

	2017	2016
Net income (loss) for the year	\$ (7,733,181)	\$ 2,296,288
Statutory income tax rate	26.0%	26.0%
Expected income tax expense (recovery)	\$ (2,010,627)	\$ 597,035
Items not deductible (taxable) for tax purposes	867,438	(53,046)
Effect of tax rate change	414,895	-
Higher rate in foreign jurisdictions	(255,334)	(18,434)
Operating loss expired	594,373	-
Change in unrecognized tax benefit	389,255	(525,555)
Deferred income tax (expense)/recovery	\$ -	\$ -

The Company recognizes deferred tax assets on losses or other deductible amounts where it is probable that sufficient future taxable profits will be available to realize such assets. The Company's unrecognized deductible temporary differences and unused tax losses for which no deferred tax asset is recognized consist of the following amounts:

	2017	2016
Tax losses carry forward	\$ 1,687,000	\$ 2,565,000
Mineral interests	1,660,000	419,000
Share issue costs	115,000	2,000
Unrecognized deferred tax assets	\$ 3,462,000	\$ 2,986,000

As at December 31, 2017, the Company has Canadian non-capital loss carry-forwards of approximately \$4,299,000 that are available to reduce taxable income in Canada. These losses expire between 2026 and 2037. As at December 31, 2017, the Company has Argentine loss carry-forwards of approximately \$2,104,000 that are available to reduce taxable income in Argentina. These losses expire between 2019 and 2022.

As at December 31, 2017, the Company has unrecognized deferred tax liabilities of \$1,194,000 due to temporary differences arising on the initial recognition of the acquisition of all of the issued and outstanding common shares of Minera Cerro Bayo S.A. and ABP Global Inc.

During the year ended December 31, 2017, the Company identified certain adjustments to its prior year deferred income tax estimates. As a result the unrecognized temporary differences have been restated to reflect these revisions. As these temporary differences are unrecognized there has been no impact on the consolidated statements of financial position, loss and comprehensive loss, equity or cash flows.

14. SUBSEQUENT EVENTS

Subsequent to the period ended December 31, 2017 the Company closed a private placement of \$2,020,022 and issued 10,100,109 units a price of \$0.20 per unit. Each unit consisted of one share and one warrant. Each warrant is exercisable for two years at a price of \$0.30. The warrants are subject to an accelerated exercise provision in the event the Company's shares trade at or greater than \$0.40 for ten consecutive trading days. In connection with the private placement, the Company paid finders' fees of \$106,660 and issued 530,800 finders' warrants with the same terms.

ABRAPLATA RESOURCE CORP.

(formerly Angel Bioventures Inc.)

Notes to the consolidated financial statements

Fifteen months ended December 31, 2017 and twelve months ended September 30, 2016

(Expressed in Canadian dollars)

14. SUBSEQUENT EVENTS (continued)

Pursuant to the anti-dilution right in the SSRM Agreement, 2,509,265 common shares were issued to SSRM. The fair value of these shares were determined to be \$752,780 based on the price of the shares issued in the concurrent private placement of \$0.30 per share, when the original 19.9% equity consideration was issued.

Subsequent to the period ended December 31, 2017 the Company issued 414,893 shares to settle debt in the amount of \$97,500.

Subsequent to the period ended December 31, 2017 the Company granted 1,125,000 stock options. The stock options have an exercise price of \$0.20 per share and are exercisable for a period of five years from the date of grant. The stock options vest 25% immediately, and the balance vests in three equal semi-annual installments commencing on the six months anniversary of the date of the grant and continuing every six months thereafter until the options are fully vested.